In preparation for the potential launch of NB32, Orexigen Therapeutics (Nasdaq: OREX) and Takeda Pharmaceutical Company Limited (“Takeda”) entered into ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE